Megestrol Acetate and Drug Resistance in Small-Cell Lung Cancer
Author Information
Author(s): L Wood, M Palmer, J Hewitt, R Urtasun, E Bruera, E Rapp, JF Thaell
Primary Institution: Cross Cancer Institute
Hypothesis
Does the addition of megestrol acetate to first-line cytotoxic therapy improve survival in small-cell lung cancer patients?
Conclusion
The addition of megestrol acetate did not improve median overall survival or time to disease progression in small-cell lung cancer patients.
Supporting Evidence
- The median time to disease progression was similar between the megestrol acetate and placebo groups.
- The median overall survival was not statistically different between the two treatment arms.
- Response rates did not show significant differences between the megestrol acetate and placebo groups.
Takeaway
The study tested if a drug called megestrol acetate could help cancer patients live longer, but it didn't make a difference.
Methodology
A double-blind, randomized placebo-controlled trial with 130 patients receiving either megestrol acetate or placebo alongside standard chemotherapy.
Limitations
P-glycoprotein levels were not measured at key points, limiting the ability to assess the drug's effect on drug resistance.
Participant Demographics
52% of patients had limited disease and 48% had advanced disease; mean age was around 60 years.
Want to read the original?
Access the complete publication on the publisher's website